Literature DB >> 19055211

Idiopathic anaphylaxis successfully treated with omalizumab.

Jeremy D Jones, Samuel R Marney, John M Fahrenholz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19055211     DOI： 10.1016/S1081-1206(10)60296-7

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  14 in total

Review 1.  Pathogenesis, newly recognized etiologies, and management of idiopathic anaphylaxis.

Authors:  James L Kuhlen; Yamini V Virkud
Journal:  Discov Med       Date:  2015-02       Impact factor: 2.970

Review 2.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

3.  Omalizumab's role in the treatment of steroid dependent malignant idiopathic anaphylaxis.

Authors:  Öner Özdemir; Hayrunnisa Bekis Bozkurt; Bahri Elmas
Journal:  Turk Pediatri Ars       Date:  2017-06-01

Review 4.  Use of omalizumab in the treatment of food allergy and anaphylaxis.

Authors:  Jay A Lieberman; Mirna Chehade
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

5.  The bee sting that was not: an unusual case of hymenoptera anaphylaxis averted in a patient treated with omalizumab for asthma.

Authors:  Evelyn M Slaughter; Nathan Boyer; Steven Bennett
Journal:  Case Rep Med       Date:  2014-08-12

Review 6.  Management and Prevention of Anaphylaxis.

Authors:  Anne-Marie Irani; Elias G Akl
Journal:  F1000Res       Date:  2015-12-22

7.  Exercise-induced anaphylaxis: a case report and review of the diagnosis and treatment of a rare but potentially life-threatening syndrome.

Authors:  Nathan T Jaqua; Matthew R Peterson; Karla L Davis
Journal:  Case Rep Med       Date:  2013-03-27

8.  Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Authors:  Cristoforo Incorvaia; Marina Mauro; Marina Russello; Chiara Formigoni; Gian Galeazzo Riario-Sforza; Erminia Ridolo
Journal:  Drug Des Devel Ther       Date:  2014-02-07       Impact factor: 4.162

9.  Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy.

Authors:  Jaechun Lee
Journal:  Asia Pac Allergy       Date:  2014-04-29

Review 10.  Idiopathic Anaphylaxis.

Authors:  Bright I Nwaru; Sangeeta Dhami; Aziz Sheikh
Journal:  Curr Treat Options Allergy       Date:  2017-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.